Daclizumab versus Antithymocyte Globulin in High-Immunological-Risk Renal Transplant Recipients
Open Access
- 1 June 2009
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 20 (6), 1385-1392
- https://doi.org/10.1681/asn.2008101037
Abstract
Nondepleting anti-CD25 monoclonal antibodies (daclizumab) and depleting polyclonal antithymocyte globulin (Thymoglobulin) both prevent acute rejection, but these therapies have not been directly compared in a high-risk, HLA-sensitized renal transplant population. We randomly assigned 227 patients, who were about to receive a kidney graft from a deceased donor, to either Thymoglobulin or daclizumab if they met one of the following risk factors: current panel reactive antibodies (PRA) >30%; peak PRA >50%; loss of a first kidney graft from rejection within 2 yr of transplantation; or two or three previous grafts. Maintenance immunosuppression comprised tacrolimus, mycophenolate mofetil, and steroids. Compared with the daclizumab group, patients treated with Thymoglobulin had a lower incidence of both biopsy-proven acute rejection (15.0% versus 27.2%; P = 0.016) and steroid-resistant rejection (2.7% versus 14.9%; P = 0.002) at one year. One-year graft and patient survival rates were similar between the two groups. In a comparison of rejectors and nonrejectors, overall graft survival was significantly higher in the rejection-free group (87.2% versus 75.0%; P = 0.037). In conclusion, among high-immunological-risk renal transplant recipients, Thymoglobulin is superior to daclizumab for the prevention of biopsy-proven acute rejection, but there is no significant benefit to one-year graft or patient survival.This publication has 23 references indexed in Scilit:
- Rituximab and Intravenous Immune Globulin for Desensitization during Renal TransplantationThe New England Journal of Medicine, 2008
- Expanding Kidney Paired Donation Through Participation by Compatible PairsAmerican Journal of Transplantation, 2007
- Posttransplant Prophylactic Intravenous Immunoglobulin in Kidney Transplant Patients at High Immunological Risk: A Pilot StudyAmerican Journal of Transplantation, 2007
- Results of an International, Randomized Trial Comparing Glucose Metabolism Disorders and Outcome with Cyclosporine Versus TacrolimusAmerican Journal of Transplantation, 2007
- Disassociation Between Risk of Graft Loss and Risk of Non-Hodgkin Lymphoma With Induction Agents in Renal Transplant RecipientsTransplantation, 2006
- A Comparison of Plasmapheresis Versus High-Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific AlloantibodyAmerican Journal of Transplantation, 2006
- Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial dataBMJ, 2005
- A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipientsClinical Transplantation, 2005
- The Banff 97 working classification of renal allograft pathologyKidney International, 1999
- EFFICACY OF REJECTION PROPHYLAXIS WITH OKT3 IN RENAL TRANSPLANTATIONTransplantation, 1995